- Home
- NMS vs KPTI Comparison
NMS vs KPTI Comparison
Compare NMS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- KPTI
- Stock Information
- Founded
- NMS 1993
- KPTI 2008
- Country
- NMS United States
- KPTI United States
- Employees
- NMS N/A
- KPTI N/A
- Industry
- NMS Finance Companies
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- NMS Finance
- KPTI Health Care
- Exchange
- NMS Nasdaq
- KPTI Nasdaq
- Market Cap
- NMS 71.8M
- KPTI 66.7M
- IPO Year
- NMS N/A
- KPTI 2013
- Fundamental
- Price
- NMS $12.40
- KPTI $7.53
- Analyst Decision
- NMS
- KPTI Strong Buy
- Analyst Count
- NMS 0
- KPTI 5
- Target Price
- NMS N/A
- KPTI $61.00
- AVG Volume (30 Days)
- NMS 12.0K
- KPTI 144.0K
- Earning Date
- NMS 01-01-0001
- KPTI 05-07-2025
- Dividend Yield
- NMS 4.11%
- KPTI N/A
- EPS Growth
- NMS N/A
- KPTI N/A
- EPS
- NMS N/A
- KPTI N/A
- Revenue
- NMS N/A
- KPTI $145,237,000.00
- Revenue This Year
- NMS N/A
- KPTI $4.37
- Revenue Next Year
- NMS N/A
- KPTI $19.07
- P/E Ratio
- NMS N/A
- KPTI N/A
- Revenue Growth
- NMS N/A
- KPTI N/A
- 52 Week Low
- NMS $9.21
- KPTI $5.90
- 52 Week High
- NMS $12.18
- KPTI $24.75
- Technical
- Relative Strength Index (RSI)
- NMS 43.14
- KPTI 43.25
- Support Level
- NMS $12.35
- KPTI $5.90
- Resistance Level
- NMS $12.50
- KPTI $8.45
- Average True Range (ATR)
- NMS 0.07
- KPTI 1.06
- MACD
- NMS -0.00
- KPTI -0.01
- Stochastic Oscillator
- NMS 6.67
- KPTI 36.38
Stock Price Comparison Chart: NMS vs KPTI
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.